Olatec Therapeutics LLC
11
3
4
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Role: lead
A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease
Role: collaborator
Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
Role: collaborator
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Role: collaborator
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
Role: lead
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
Role: lead
Study of Dapansutrile Capsules in Heart Failure
Role: lead
Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain
Role: lead
Phase 1 Safety and PK Study of OLT1177 Capsules
Role: lead
Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee
Role: lead
Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects
Role: lead
All 11 trials loaded